# US 2024/0199822 A1 · Method for preparing acylated crosslinked glycosaminoglycans

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199822 A1
- Document ID: US20240199822A1
- Status: Published application
- Kind: A1
- Application number: 18/590,007
- Filed: 2024-02-28
- Published: 2024-06-20
- Earliest claimed: 2015-12-29
- Assignees: Galderma Holding SA
- Applicants: Galderma Holding SA
- Inventors: Johan OLSSON; Craig Steven HARRIS
- Web page: https://patentgrep.com/patent/US20240199822A1

## CPC

- C08J 3/075: Macromolecular gels
- A61K 8/042: {Gels}
- A61K 8/73: Polysaccharides
- A61K 8/735: {Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/738: Cross-linked polysaccharides
- A61P 17/00: Drugs for dermatological disorders
- A61Q 19/00: Preparations for care of the skin
- C07C 209/62: by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds (C07C209/24 takes precedence)
- C07C 213/00: Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C 269/06: by reactions not involving the formation of carbamate groups
- C07F 7/083: {Syntheses without formation of a Si-C bond}
- C08B 37/0063: {Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan}
- C08B 37/0069: {Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof}
- C08B 37/0072: {Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates}
- C08J 3/24: Crosslinking, e.g. vulcanising, of macromolecules (mechanical aspects B29C35/00; crosslinking agents C08K)
- C08J 7/14: with acids, their salts or anhydrides
- C08K 5/09: Carboxylic acids; Metal salts thereof; Anhydrides thereof
- C08L 5/00: Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L 5/08: Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
- C07C 2603/18: Fluorenes; Hydrogenated fluorenes
- C08J 2305/00: Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J 2305/08: Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
- C08J: WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H (working, e.g. shaping, of plastics B29)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C08K: Use of inorganic or non-macromolecular organic substances as compounding ingredients (paints, inks, varnishes, dyes, polishes, adhesives C09)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

A method of preparing a hydrogel product including crosslinked glycosaminoglycan molecules, said method including: i) providing a glycosaminoglycan crosslinked by amide bonds, wherein the crosslinked glycosaminoglycans include residual amine groups; and ii) acylating residual amine groups of the crosslinked glycosaminoglycans provided in i) to form acylated crosslinked glycosaminoglycans.

## Claims

### Claim 1

A method of providing corrective or aesthetic treatment, the method comprising:
administering to a subject a therapeutically effective amount of a composition comprising a hydrogel product comprising acylated crosslinked glycosaminoglycans (GAGs), wherein the crosslinked GAGs comprise:
an at least partially deacetylated GAG comprising free amine groups, wherein the at least partially deacetylated GAG is crosslinked to a second GAG by amide bonds,
wherein the hydrogel product has residual free amine groups and a degree of acetylation of at least 95%.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the at least partially deacetylated GAG is selected from the group consisting of deacetylated hyaluronic acid, deacetylated chondroitin, and deacetylated chondroitin sulfate, and mixtures thereof.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the at least partially deacetylated GAG is deacetylated hyaluronic acid.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the at least partially deacetylated GAG has a degree of acetylation of 95% or less.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the at least partially deacetylated GAG has a degree of acetylation of 93% or less.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the at least partially deacetylated GAG has a weight average molecular weight of 0.1 MDa or more.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the second GAG is selected from the group consisting of hyaluronic acid, chondroitin, and chondroitin sulfate, and mixtures thereof.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the second GAG is hyaluronic acid.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the second GAG is non-deacetylated.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the crosslinked GAGs comprise two different GAGs selected from hyaluronic acid, chondroitin, chondroitin sulphate, heparin sulphate, heparosan, heparin, dermatan sulphate, and keratin sulphate.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the crosslinked GAGs are substantially free of ester crosslinks.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the hydrogel product is based entirely on carbohydrate type structures.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the composition an injectable composition.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the hydrogel product is suspended in saline solution.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the pH of the saline solution is 7.4.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the crosslinked glycosaminoglycans (GAGs) are present in the form of gel particles having an average size of 0.01-5 mm.

### Claim 17 (depends on 1)

The method according to claim 1, wherein at least 50% by weight of GAG molecules in the hydrogel product are crosslinked GAGs.

### Claim 18 (depends on 1)

The method according to claim 1, wherein the composition is topically administered to skin.

### Claim 19 (depends on 1)

The method according to claim 1, wherein the composition is administered by injection.

### Claim 20 (depends on 1)

The method according to claim 1, wherein the at least partially deacetylated glycosaminoglycan is prepared by:
(a) reacting a GAG comprising N-acetyl groups with hydroxylamine (NH2OH), or a salt thereof, at a temperature of 100° C. or less for 2-200 hours to form the at least partially deacetylated GAG, and
(b) recovering the at least partially deacetylated GAG.
